Hepburn J et al., 2022-11-08: Pilot clinical study whose protocol is the clearest published example of an oral methylene blue dose being escalated according to the patient's response. It states a starting range, a frequency change and a ceiling dose.
MB capsules were initially administered orally in a dose range of 1.5 to 2 mg/kg 12-hourly. We subsequently transitioned to 8-hourly based on observed patient responses, with a maximum dosage of 200 mg.
Hepburn J et al., 2022-11-08: Pilot clinical study whose protocol is the clearest published example of an oral methylene blue dose being escalated according to the patient's response. It states a starting range, a frequency change and a ceiling dose. Study type: open-label pilot clinical study (uncontrolled). N=8 adults with COVID-19. Country: Bahamas (remote care programme). Dose: oral MB capsules 1.5-2 mg/kg 12-hourly, later 8-hourly, maximum 200 mg per dose; sublingual/oral PBM added in some patients. Route: oral capsules plus local photodynamic inactivation in nose and mouth. Duration: 8 treatments per protocol; 12-month follow-up. Comparator: none (no control group). Funder: Contigo Foundation (per acknowledgement). COI: 'The authors declare no conflict of interest. Juliette Hepburn customized the LED treatment device and modified the treatment protocol originally developed by Detlef Schikora. Juliette Hepburn is the Medical Director of Luminnova Health which filed an international patent along with Detlef Schikora…' Note: this is an escalated regimen published by its authors, not a titration schedule validated in a controlled trial. Also filed as MTD-038, MTD-100, MTF-58 (claims C3, C7, F1, F3). Study type: uncontrolled series.
